TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

16 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

15 studies on the map

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity — University of Connecticut, StorrsSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetPRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaSafety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaSafety and Efficacy of ONT01 in Lupus — Hospital for Special Surgery, New YorkEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — Research Site, Las VegasClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Local Institution - 0001, Farmington